Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

ABSTRACT:

SUBMITTER: Hodi FS 

PROVIDER: S-EPMC5630525 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature